Cerecin

Executive Summary

Cerecin is a private, clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing small molecule therapeutics for neurological disorders, with a primary focus on epilepsy and Alzheimer's disease. Founded in 2018, the company addresses significant unmet medical needs in central nervous system (CNS) disorders, an area where existing treatments often provide limited efficacy or suffer from side effects. Cerecin's pipeline is built on a proprietary platform that targets novel mechanisms in disease pathology, aiming to offer disease-modifying or symptom-controlling therapies. The company operates in a competitive landscape, with several large players and biotechs pursuing similar indications, but its early-stage, innovative approach could differentiate it if clinical data prove positive. As a private entity, Cerecin's funding history and valuation are not publicly disclosed, but its focus on high-need CNS conditions positions it for potential strategic partnerships or acquisition interest upon successful clinical milestones. The company's progress through the clinic will be critical, as positive trial results could unlock significant value, though the inherent risks of CNS drug development remain substantial.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1/2 trial for lead epilepsy candidate40% success
• Q1 2027Presentation of preclinical data for Alzheimer's program at major conference60% success
• Q4 2026Potential partnership or licensing deal for CNS platform30% success